KalVista Pharmaceuticals (NASDAQ:KALV) Given Buy Rating at HC Wainwright

KalVista Pharmaceuticals (NASDAQ:KALV)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $20.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 53.37% from the company’s previous close.

Separately, Needham & Company LLC dropped their price target on shares of KalVista Pharmaceuticals from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Friday.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV opened at $13.04 on Monday. The stock has a market capitalization of $557.33 million, a P/E ratio of -3.84 and a beta of 0.91. The business has a 50 day simple moving average of $11.86 and a 200 day simple moving average of $12.45. KalVista Pharmaceuticals has a one year low of $7.21 and a one year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, July 11th. The specialty pharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.29). Equities analysts expect that KalVista Pharmaceuticals will post -2.65 earnings per share for the current year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 21,959 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $11.76, for a total value of $258,237.84. Following the completion of the transaction, the chief executive officer now owns 216,387 shares in the company, valued at approximately $2,544,711.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Benjamin L. Palleiko sold 7,465 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $11.53, for a total value of $86,071.45. Following the transaction, the chief executive officer now owns 224,547 shares in the company, valued at $2,589,026.91. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Benjamin L. Palleiko sold 21,959 shares of the stock in a transaction on Monday, May 20th. The shares were sold at an average price of $11.76, for a total value of $258,237.84. Following the transaction, the chief executive officer now directly owns 216,387 shares of the company’s stock, valued at $2,544,711.12. The disclosure for this sale can be found here. Over the last three months, insiders sold 37,512 shares of company stock valued at $439,424. 12.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KALV. Vanguard Group Inc. boosted its position in KalVista Pharmaceuticals by 9.6% during the third quarter. Vanguard Group Inc. now owns 1,732,489 shares of the specialty pharmaceutical company’s stock worth $16,684,000 after purchasing an additional 151,808 shares during the period. SG Americas Securities LLC raised its holdings in KalVista Pharmaceuticals by 5.1% during the 4th quarter. SG Americas Securities LLC now owns 137,817 shares of the specialty pharmaceutical company’s stock valued at $1,688,000 after acquiring an additional 6,670 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth $49,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of KalVista Pharmaceuticals in the fourth quarter worth $126,000. Finally, AJOVista LLC purchased a new position in shares of KalVista Pharmaceuticals in the fourth quarter valued at $60,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.